Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.
The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs.
Gupta
Seema
S
Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India.
Farooque
Abdullah
A
Adhikari
J S
JS
Singh
Saurabh
S
Dwarakanath
B S
BS
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D003131:Combined Modality Therapy; D003847:Deoxyglucose / Q000008:administration & dosage*; D005947:Glucose / Q000378:metabolism; D009374:Neoplasms, Experimental / Q000378:metabolism* / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods*
D003847:Deoxyglucose; D005947:Glucose